Raine AEG. Renal abnormality in congestive heart failure. In: Fozzard HA et al., eds. The Heart and Cardiovascular System. New York: Raven Press, 1992:1379–91.
Google Scholar
Yuen JL, Sonnenblick EH, LeJemtel TH. Principles of inotropic therapy in heart failure. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:837–844.
Google Scholar
Cohn JN. Principles of vasodilator therapy in congestive heart failure: Impact on mortality. In: Singh BN, Dzau Vj, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:791–796.
Google Scholar
Cody RJ. Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure. Am J Cardiol 1989;63:31A-34A.
PubMed
Article
CAS
Google Scholar
Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 1993;22(Suppl A):119A-26A.
PubMed
CAS
Article
Google Scholar
Fischer TA, Erbel R, Treese N. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 1992;44:928–945.
PubMed
Article
CAS
Google Scholar
Blaufox MD, Merrill JP. Simplified Hippuran clearance: Measurement of renal function in man with simplified Hippuran clearance. Nephron 1955;3:274–281.
Article
Google Scholar
Fine EJ, Axelrod M, Gorkin H, Saleemi K, Blaufoux MD. Measurement of effective renal plasma flow: A comparison of methods. J Nucl Med 1987;28:1939–1400.
Google Scholar
Laragh JH, Brenner BM. Hypertension Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1990.
Google Scholar
Glantz AS. Primer on Biostatistics. New York: McGraw-Hill, 1992.
Google Scholar
Gardner MJ, Altman DG. Statistics with Confidence-Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1989.
Google Scholar
Goldberg LI. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972; 24:1–29.
PubMed
CAS
Google Scholar
Lokhandwala MF, Barrett RJ. Cardiovascular dopamine receptors: Physiological, pharmaceutical and therapeutic implications. J Auton Pharmacol 1982;3:189–215.
Article
Google Scholar
Goldberg LI, Hsieh YY, Resnekov L. Newer catecholamines for treatment of heart failure and shock: An update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 1977;4:327–340.
Article
Google Scholar
Robie NW, Goldberg LI: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine. Am Heart J 1975;90:340–347.
PubMed
Article
CAS
Google Scholar
Van der Leyen H. Phosphodiesterase inhibition by new cardiotonic agents: Mechanism of action and possible clinical relevance in the therapy of congestive heart failure. Klin Wochenschr 1989;67:605.
PubMed
Article
Google Scholar
Cody RJ, Kubo SH, Covit AB et al. Regional blood flow and neurohumoral responses to milrinone in congestive heart failure. Clin Pharmacol Ther 1986;39:128.
PubMed
CAS
Google Scholar
Dazau VJ, Pratt RE. Cardiovascular pharmacology of angiotensin-converting enzyme inhibitors. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:237–247.
Google Scholar
Iervasi G, Clerico A, Pilo A et al. Kinetic study of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy. Evidence for resistance to the biological effects of the hormone even in patients with mild myocardial involvement. J Cardiovasc Pharmacol 1994;24:626–637.
PubMed
Article
CAS
Google Scholar